The clinical findings associated with PLP1 mutations are spread over a continuous spectrum extending from the most severe form of PMD to the relatively mild late‐onset type 2 spastic paraplegia, which led to the concept of PLP1‐related disorders 10. This evidence concerns the gene PLP1 and Spastic paraplegia type 2.